Windtree Therapeutics INC /DE/ 8-K filings

Eric L. Curtis has resigned as President and Chief Operating Officer of Windtree Therapeutics, Inc., effective January 5, 2026.

Windtree Therapeutics issued $857,142.86 in senior convertible promissory notes to fund an acquisition and general corporate purposes.

Windtree Therapeutics, Inc. issued $1.6 million in senior convertible promissory notes to institutional investors, maturing in October 2026 with a 10% interest rate.

Windtree Therapeutics' subsidiary, WINT Real Estate, LLC, settled a dispute over a terminated real estate purchase agreement, recovering $750,000 of the $3 million earnest money.

Windtree Therapeutics announces the immediate resignation of its Senior Vice President and Chief Medical Officer, Steven G. Simonson, M.D.

Windtree Therapeutics stockholders approved all nine proposals at a Special Meeting, including significant share issuances, an increase in authorized capital, and a reverse stock split.

Windtree Therapeutics, Inc. announced its common stock will be delisted from Nasdaq and will begin trading on the over-the-counter market.

Windtree Therapeutics, Inc. has terminated its SEISMiC-C clinical study for istaroxime due to limited resources and a strategic shift towards broader acute heart failure development.

Windtree Therapeutics announced positive interim analysis results from its SEISMiC C Phase 2 study of istaroxime in severe cardiogenic shock patients, showing consistency with prior studies and no new safety signals.

Windtree Therapeutics announces the resignation of Audit Committee Chair Leanne Kelly and the immediate appointment of Andrew Kucharchuk to its Board of Directors and as new Audit Committee Chair.

Windtree Therapeutics, a biotechnology company, announced new financing agreements totaling up to $520 million, primarily an equity line of credit and a convertible note, with 99% of proceeds earmarked for acquiring BNB cryptocurrency as part of an innovative treasury strategy.

A diversified company known for its therapeutic pipelines is launching a significant BNB crypto treasury strategy with an initial $60 million investment, aiming to become the first NASDAQ-listed entity offering direct exposure to the Binance Smart Chain Ecosystem.

Windtree Therapeutics, Inc. has raised $253,333 in gross proceeds through the issuance of senior unsecured convertible promissory notes and warrants to fund operational expenses, under terms indicating significant financial pressure.

Windtree Therapeutics, Inc. has entered into a high-interest convertible note and warrant financing agreement for $150,000, while simultaneously announcing the resignation of its CFO and a dispute over a $3 million earnest money payment related to a terminated real estate deal.

Windtree Therapeutics, Inc. has received a deficiency letter from Nasdaq for failing to meet the minimum bid price requirement, potentially leading to delisting.

Windtree Therapeutics, Inc. has secured new convertible debt and is pursuing a dual strategy of acquiring an environmental services company and divesting preclinical oncology assets, while simultaneously addressing significant existing financial defaults.

Windtree Therapeutics announced its Q1 2025 financial results, highlighting a new corporate strategy focused on revenue generation and pipeline advancement.

Windtree Therapeutics enters an agreement to potentially acquire a multifamily property in Houston, aiming to generate consistent revenue while advancing its therapeutic pipeline.

Windtree Therapeutics secures $2.5 million through a private placement of Series D Convertible Preferred Stock to strengthen its financial footing.

Craig Fraser resigned from Windtree Therapeutics' Board of Directors, effective immediately, reducing the board size from five to four members.

Windtree Therapeutics announced its year-end 2024 financial results, highlighting progress in clinical development, business development, and a new corporate strategy focused on acquiring revenue-generating biotech companies.

Windtree Therapeutics enters into a material agreement, issuing a convertible promissory note to institutional investors for gross proceeds of $250,000.

Windtree Therapeutics announces a License and Supply Agreement with Evofem Biosciences to become the sourcing partner for PHEXXI, aiming to reduce manufacturing costs and expand global availability.

Windtree Therapeutics issues senior secured notes for $250,000 and partners with Evofem Biosciences to supply Phexxi outside the US.

Windtree Therapeutics enacts a 1-for-50 reverse stock split to meet Nasdaq's minimum bid price requirement and maintain its listing.

Windtree Therapeutics amends its previous filing to provide further details on the conversion of Series C Preferred Stock and the related reduction in warrant exercise price.

Windtree Therapeutics' stockholders approved a reverse stock split but rejected an increase in shares authorized under the company's equity incentive plan at a special meeting held on February 3, 2025.

Windtree Therapeutics is offering holders of its Series C Convertible Preferred Stock a reduced conversion price of $0.1608 in exchange for agreeing to certain forbearance terms.

Windtree Therapeutics has appointed Leanne Kelly, a seasoned financial executive, to its board of directors as an independent director and chair of the audit committee.

Windtree Therapeutics is shifting its strategy to acquire revenue-generating companies with FDA-approved products while continuing to advance its existing cardiovascular and oncology pipeline.